Chen C L, Sheen T S, Lou I U, Huang A C
Department of Pathology, China Medical College Hospital, Taichung, Taiwan.
Hum Pathol. 2001 Nov;32(11):1240-4. doi: 10.1053/hupa.2001.28950.
Radiotherapy is the modality of choice for the treatment of nasopharyngeal carcinoma (NPC). However, systemic chemotherapy has recently been found to play an increasing role in the treatment of advanced or metastatic disease. The status of drug resistance gene expression that has crucial impact on chemotherapy has not been fully addressed for patients with NPC. In this study, we examined the expression of multidrug resistance 1 (MDR-1) and glutathione-S-transferase-Pi (GST-Pi) in primary, recurrent, and metastatic NPC using results of immunohistochemical examinations. The results were correlated with the expression of Epstein-Barr virus (EBV) latent protein, latent membrane protein 1 (LMP1), and clinicopathologic features, including stage, histopathologic types, and survival rates. MDR-1 protein expression was detected in 18 (12.6%) of 143 patients with primary NPC, 14 (32.6%) of 43 with recurrent NPC, and O (0%) of 20 with metastatic NPC, whereas 83 (58%) of 143 patients with primary NPC, 30 (69.8%) of 43 with recurrent NPC, and 13 (65%) of 20 with metastatic NPC expressed GST-Pi. EBV-LMP1 was expressed in 59 (41.3%) of 143 patients with primary NPC, 23 (53.5%) of 43 with recurrent NPC, and 9 (45%) of 20 with metastatic NPC. Simultaneous expression of MDR1 and GST-Pi was observed in 13 (72.2%) of 18 patients with primary NPC and 12 (85.7%) of 14 with recurrent NPC. The expression of LMP1 was detected in only 6 of the 13 patients with primary NPC and 6 of the 12 with recurrent NPC. We concluded that the expression of GST-Pi was more frequent in NPC tumor tissues than the expression of MDR-1. The expression of MDR-1 correlated with clinicopathologic features of primary NPC, including the histopathologic types and survival rates, but not with disease stage. The expression of GST-Pi did not correlate with clinicopathologic features. The expression of MDR-1 and GST-Pi did not correlate with expression of EBV-LMP1 for patients with NPC.
放射治疗是鼻咽癌（NPC）治疗的首选方式。然而，近来发现全身化疗在晚期或转移性疾病的治疗中发挥着越来越重要的作用。对于鼻咽癌患者，对化疗有至关重要影响的耐药基因表达状况尚未得到充分研究。在本研究中，我们利用免疫组化检查结果检测了原发性、复发性和转移性鼻咽癌中多药耐药1（MDR-1）和谷胱甘肽-S-转移酶-Pi（GST-Pi）的表达。结果与爱泼斯坦-巴尔病毒（EBV）潜伏蛋白、潜伏膜蛋白1（LMP1）的表达以及临床病理特征（包括分期、组织病理学类型和生存率）相关。在143例原发性鼻咽癌患者中，18例（12.6%）检测到MDR-1蛋白表达；43例复发性鼻咽癌患者中，14例（32.6%）检测到；20例转移性鼻咽癌患者中，0例（0%）检测到。而在143例原发性鼻咽癌患者中，83例（58%）表达GST-Pi；43例复发性鼻咽癌患者中，30例（69.8%）表达；20例转移性鼻咽癌患者中，13例（65%）表达。18例原发性鼻咽癌患者中有13例（72.2%）、14例复发性鼻咽癌患者中有12例（85.7%）同时检测到MDR1和GST-Pi表达。在13例原发性鼻咽癌患者中，仅6例检测到LMP1表达；12例复发性鼻咽癌患者中，仅6例检测到。我们得出结论，GST-Pi在鼻咽癌肿瘤组织中的表达比MDR-1更常见。MDR-1的表达与原发性鼻咽癌的临床病理特征相关，包括组织病理学类型和生存率，但与疾病分期无关。GST-Pi的表达与临床病理特征无关。对于鼻咽癌患者，MDR-1和GST-Pi的表达与EBV-LMP1的表达无关。
